|
| Status |
Public on May 19, 2014 |
| Title |
hiPSCCM_CVB3_IFNB1_Rep2 |
| Sample type |
RNA |
| |
|
| Source name |
hiPSC-CMs
|
| Organism |
Homo sapiens |
| Characteristics |
cell type: hiPSC-CMs (human induced pluripotent stem cell-derived cardiomyocytes)
infection: coxsackievirus CVB3
treatment: 8 ng/mL interferon beta 1, 12 hour pretreatment
|
| Treatment protocol |
Two treatment groups were established: 1 receiving interferon beta and 1 untreated control group. Interferon-treatment group received 8ng/mL interferon beta 1 treatment for 12 hours prior to coxsackievirus B3 infection. Both groups were infected with CVB3 at MOI 5. Cells were harvested at 8 hours after infection.
|
| Growth protocol |
hiPSC-CMs after 30 days of differentiation (see Lian et al 2012) were purified and replated into 96 wells at a density of 40,000 cells per well.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
All samples were harvested in Trizol. RNA was extracted with the miRNeasy kit (Qiagen). cDNA was synthesized using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA)
|
| Label |
biotin
|
| Label protocol |
Performed at the Pan facility @ http://cmgm.stanford.edu
|
| |
|
| Hybridization protocol |
Performed at the Pan facility @ http://cmgm.stanford.edu
|
| Scan protocol |
Performed at the Pan facility @ http://cmgm.stanford.edu
|
| Description |
Interferon beta-treated, CVB3-infected hiPSC-CMs (sample 2)
|
| Data processing |
Data were processed using Affymetrix expression console
HuGene-2_0-st.pgf
HuGene-2_0-st.mps
|
| |
|
| Submission date |
May 19, 2014 |
| Last update date |
May 19, 2014 |
| Contact name |
Jared Churko |
| E-mail(s) |
jchurko@stanford.edu
|
| Organization name |
Stanford
|
| Department |
Radiology
|
| Street address |
265 Campus Dr G1105 SIM1
|
| City |
Stanford |
| State/province |
CA |
| ZIP/Postal code |
94305 |
| Country |
USA |
| |
|
| Platform ID |
GPL16686 |
| Series (1) |
| GSE57781 |
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3-Induced Myocarditis and Antiviral Drug Screening Platform |
|
